NeuroVive Pharmaceutical AB Ret. on equity
What is the Ret. on equity of NeuroVive Pharmaceutical AB?
The Ret. on equity of NeuroVive Pharmaceutical AB is -69.63%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Miscellaneous sector on LSE compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with ret. on equity similar to NeuroVive Pharmaceutical AB
- Talga Resources has Ret. on equity of -69.77%
- Kinetiko has Ret. on equity of -69.76%
- SinoMab BioScience has Ret. on equity of -69.74%
- Rhino Resource Partners LP has Ret. on equity of -69.70%
- Haydale Graphene Industries plc has Ret. on equity of -69.66%
- Coppercorp Resources Inc has Ret. on equity of -69.65%
- NeuroVive Pharmaceutical AB has Ret. on equity of -69.63%
- Ether Capital has Ret. on equity of -69.63%
- Lions Bay Capital has Ret. on equity of -69.62%
- STRATA Skin Sciences Inc has Ret. on equity of -69.56%
- Dynamo Capital has Ret. on equity of -69.39%
- Mer Telemanagement Solutions has Ret. on equity of -69.37%
- Praxis Home Retail has Ret. on equity of -69.32%